▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #265 by analyst upside · 2026-09-09
CDXS
Codexis, Inc.
Healthcare · Market Cap $157M · P/E 0x
ANALYST PRICE TARGET
+342.9%
implied upside to consensus target
Current Price $1.43
Consensus Target $6.33
Bull Target $11.0
Bear Target $2.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
2
Sell
0
52-Week Low $0.96
52-Week High $2.98
YTD Return -11.2%
FUNDAMENTALS
Market Cap $157M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.33
PEG Ratio 13.53
Dividend Yield N/A
Revenue (TTM) $78M
Profit Margin -39.6%
52-WEEK RANGE
52-Week Low $0.96
52-Week High $2.98
Current Price $1.43
Bear Target $2.0
Bull Target $11.0
● Now $1.43 ● Target $6.33
TRADING DATA
Avg Volume 1.2M
YTD Return -11.2%
Analyst Count 6
Consensus Buy
Upside to Target +342.9%
Last Updated 2026-09-09

ANALYST SUMMARY

Codexis, Inc. (CDXS) is currently trading at $1.43 with a Wall Street consensus price target of $6.33, implying potential upside of 342.9% over the next 12 months. 6 analysts currently cover CDXS, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $2.0.

CDXS operates in the Healthcare sector with a market capitalisation of $157M. The stock is down 11.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.96 – $2.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ZVRA +97.2%
Zevra Therapeutics, Inc.
$753M · P/E 13.6x · Buy
TCMD +79.5%
Tactile Systems Technology, Inc.
$492M · P/E 20.3x · Buy
JYNT +22.1%
The Joint Corp.
$116M · P/E 58.5x · Hold
SLP -6.4%
Simulations Plus, Inc.
$373M · P/E 46.0x · Hold
OMCL +70.8%
Omnicell, Inc.
$2B · P/E 40.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CDXS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Overweight → Overweight 2026-08-17 14% win rate (7 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-11-22 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-11-15 40% win rate (10 calls)
Benchmark reit
Hold 2024-11-04 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-20 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-08-29 40% win rate (10 calls)
Benchmark ↓ Downgrade
Buy → Hold 2024-08-19 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-08-09 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
29
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →